A phase 1 single-center, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of Ozanimod in healthy volunteers

Trial Profile

A phase 1 single-center, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of Ozanimod in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Multiple sclerosis; Ulcerative colitis
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 11 Apr 2017 Results published in the Journal of Clinical Pharmacology
    • 18 May 2013 Results presented at the Digestive Disease Week 2013.
    • 13 Oct 2012 Results presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top